Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEPHROS INCNEPH · Entity 7279 | Director | December 19, 2018 | December 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEPHROS INC
Report date December 19, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.65 · Expires 2028-12-19 | Direct | 46,457 |
Reported balance
After 2018-12-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-19 · Grant · Acquired 46,457 · Balance 46,457 F4: On December 19, 2018, the Company granted an option to purchase 46,457 shares of common stock of the Company (the "Option") in respect of the service by Mr. Pinto as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 15,486 shares on each of 12/19/18 and 12/19/19, and as to 15,485 shares on 12/19/20. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2025-08-14 | Direct | 59,155 |
Reported balance
Holding disclosure · report date 2018-12-19 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 59,155 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.40 · Expires 2026-08-24 | Direct | 33,880 |
Reported balance
Holding disclosure · report date 2018-12-19 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 33,880 F2: Fully exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2027-12-20 | Direct | 40,284 |
Reported balance
Holding disclosure · report date 2018-12-19 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 40,284 F3: The option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19. |
| Common StockSEC Table I · non-derivative | Direct | 204,118 |
Reported balance
Holding disclosure · report date 2018-12-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 204,118 F1: Includes 47,673 shares of restricted stock that vest on 6/14/19. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 47,673 shares of restricted stock that vest on 6/14/19.
F2: Fully exercisable.
F3: The option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19.
F4: On December 19, 2018, the Company granted an option to purchase 46,457 shares of common stock of the Company (the "Option") in respect of the service by Mr. Pinto as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 15,486 shares on each of 12/19/18 and 12/19/19, and as to 15,485 shares on 12/19/20.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2018 Filed Dec 21, 2018 21:53 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 46,457 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0000914190-18-000583 · edgar.xml · derivative · entry 5 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,457 Underlying: Common Stock · 46,457 shares Expires 2028-12-19 F4 · derivative.exercise_date: On December 19, 2018, the Company granted an option to purchase 46,457 shares of common stock of the Company (the "Option") in respect of the service by Mr. Pinto as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 15,486 shares on each of 12/19/18 and 12/19/19, and as to 15,485 shares on 12/19/20. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 22:27 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 73,343 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000568 · edgar.xml · nonDerivative · entry 1 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,788 F1 · shares: On December 14, 2018, the Company granted 73,343 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Pinto in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| December 14, 2018 Filed Dec 20, 2018 21:12 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 47,673 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000575 · edgar.xml · nonDerivative · entry 1 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,118 F1 · shares: On December 14, 2018, the Company granted 47,673 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Pinto in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:33 UTC | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 40,284 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000914190-17-000391 · edgar.xml · derivative · entry 4 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,284 Underlying: Common Stock · 40,284 shares Expires 2027-12-20 F4 · derivative.exercise_date: On December 20, 2017, the Company granted an option to purchase 40,284 shares of common stock of the Company (the "Option") in respect of the service by Mr. Pinto as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19. Read SEC document |
| December 20, 2017 Filed Dec 22, 2017 16:33 UTC | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 73,864 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-17-000391 · edgar.xml · nonDerivative · entry 1 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,445 F1 · shares: On December 20, 2017, the Company granted 73,864 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Pinto in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
| December 20, 2017 Filed Feb 27, 2018 21:09 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | GrantStock Option (Right to Buy) · Derivative | 40,284 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000914190-18-000090 · edgar.xml · derivative · entry 4 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,284 Underlying: Common Stock · 40,284 shares Expires 2027-12-20 F4 · derivative.exercise_date: On December 20, 2017, the Company granted an option to purchase 40,284 shares of common stock of the Company (the "Option") in respect of the service by Mr. Pinto as a member of the Board of Directors of the Company. The Option was granted under the 2015 Plan. The Option vests as to 13,428 shares on each of 12/20/17, 12/20/18 and 12/20/19. Read SEC document |
| December 20, 2017 Filed Feb 27, 2018 21:09 UTC Amendment | NEPHROS INC NEPH · Entity 7279 | GrantCommon Stock | 73,864 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-18-000090 · edgar.xml · nonDerivative · entry 1 Pinto Moshe · CIK 0001651255 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,445 F1 · shares: On December 20, 2017, the Company granted 73,864 shares of restricted stock of the Company (the "Restricted Stock") in lieu of cash fees payable to Mr. Pinto in respect of his services as a member of the Board of Directors of the Company. The Restricted Stock was granted under the Company's 2015 Equity Incentive Plan (the "2015 Plan"). The Restricted Stock vests 6 months following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.